Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Change in Cash (2021 - 2024)

Opus Genetics (IRD) has disclosed Change in Cash for 8 consecutive years, with $8.2 million as the latest value for Q4 2023.

  • On a quarterly basis, Change in Cash fell 71.68% to $8.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $7.9 million, a 56.54% decrease, with the full-year FY2024 number at -$20.2 million, down 356.51% from a year prior.
  • Change in Cash was $8.2 million for Q4 2023 at Opus Genetics, up from $2.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $28.8 million in Q4 2022 to a low of -$5.8 million in Q1 2021.
  • A 3-year average of $2.9 million and a median of -$2.0 million in 2021 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: crashed 116.29% in 2022, then surged 174.86% in 2023.
  • Opus Genetics' Change in Cash stood at -$2.0 million in 2021, then skyrocketed by 1550.55% to $28.8 million in 2022, then plummeted by 71.68% to $8.2 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Change in Cash are $8.2 million (Q4 2023), $2.4 million (Q3 2023), and $989000.0 (Q2 2023).